Registry Update

Enrollment Update: DuraGraft® Registry Enrollment as of February 2, 2018 is 1,102 patients enrolled across 27 active sites in eight countries!

The participating countries include: Austria, Germany, Ireland, Italy, Spain, Switzerland, Turkey and the United Kingdom.

Click here to view Registry Update.

Best Practices

TiProtec: A German surgeon was considering use of TiProtec, however he decided he would not use the product for the following reasons:

• Not indicated for use in CABG
• No clinical data to support safety and efficacy in CABG
• Concerns for over perfusion in patient due to high potassium levels and presence of desferoxamine.

Be sure to share this story with your customers using alternate products that are not proven or approved.

Don’t be afraid to ASK

The HALO effect is a psychological phenomenon in which we naturally assume that if a person is good at something, everything they do and all decisions they make must also be good. The same is true for how cardiac surgeons see their peers and their Key Opinion leaders. What does this mean for us? It means that we can use this same psychological phenomenon to help spread the use of DuraGraft. A well-respected surgeon or KOL who is using DuraGraft can strongly influence his/her peer to use DuraGraft simply by the fact that he/she is using DuraGraft. The peer rationalizes that if this surgeon is using DuraGraft, then using DuraGraft MUST be the right thing to do because this surgeon is highly regarded, knows what he/she is talking about and always makes the right decision. Therefore, I will follow his/her example and use DuraGraft.

As a part of Somahlution’s commercial HALO strategy, it is imperative that you encourage your local Cardiac Surgeon or supportive Key Opinion Leader to share their favorable experience with DuraGraft with other surgeons around the world who may be interested in this breakthrough innovation. We have the ability to quickly pass critical information regarding DuraGraft to others in the world-wide cardiac surgery community. This tactic, known commonly as “peer-to-peer” marketing, will help increase the DuraGraft brand strength from one locality to the other.

The HALO effect can also be put to advantage by you, the distributor, by letting your customers who are not using DuraGraft know some of the surgeons and centers that are currently using DuraGraft. This message can be further elaborated on by discussing registry activities and naming centers that have started commercial use.

DuraGraft Clinical News and Tools

Dr. Maximilian Emmert, MD, Ph.D. wrote an article which was recently published in the European Heart Journal. In this article titled “CABG in the era of modern PCI”, Dr Emmert answers the question “How to optimize coronary artery bypass grafting (CABG) to remain the gold-standard for multivessel disease?”

Dr. Emmert references DuraGraft when addressing the issue of vein graft storage. He goes on to say, “When compared with standard solutions such as saline and ex vivo blood, DuraGraft demonstrated an increased preservation and a high degree of structural viability for up to 24h with human ex vivo SVGs.”

He also says, “Initial promising results from the Boston Veterans Affairs Healthcare System were recently presented at the last annual meeting of the European Association of Cardio-Thoracic Surgery (EACTS) showing that the treatment of SVGs with DuraGraft was associated with a significant reduction of long-term complications particularly to non-fatal MI.44 In addition, a randomized, controlled with mandated MDCT imaging trial assessing safety and efficacy is underway with a focus on longitudinal graft-behavior (NCT02272582/NCT02774824)”.

For more reading on Dr. Emmerts thoughts on DuraGraft, please click here.

Abstract Summary Tools

TCT 2017
DuraGraft, a one-time intraoperative treatment against vein graft failure: A randomized multicenter trial using longitudinal MDCT angiography analysis in patients undergoing CABG was presented October 30, 2017, Denver, CO, by Louis P. Perrault.

EACTS 2016
DuraGraft, a one-time intraoperative treatment for the prevention of vein graft failure improves clinical outcomes after coronary artery bypass grafting – Long-term analysis of 2,436 consecutive patients was presented October 3, 2016, Barcelona, Spain, by Miguel Haime, MD.

Upcoming Events

SAVE THE DATE – The American Association for Thoracic Surgery will take place April 28 – May 1, 2018 at the San Diego Convention Center in San Diego, CA. Somahlution plans to sponsor a clinician lead dinner presentation highlighting the latest DuraGraft updates while engaging new clinicians. Be sure to let us know if you have surgeons from your territory or surgeons you know attending the meeting that would be interested in attending the event.

Past Events

35th Cardiovascular Surgical Symposium
Medovis featured DuraGraft at our latest meeting with additional Somahlution leadership in attendance.

Somahlution sponsored an intimate dinner event at the Society of Thoracic Surgeons in Fort Lauderdale, FL this January. Attendees included Somahlution leadership team, key clinical advisors and emerging U.S. advocates. The team discussed expansion of global strategy and further extending DuraGraft awareness in the cardiac surgery community through education and data.

Somahlution team members participated at the IACTS Convention in Visakhapatnam, India. Three hundred surgeons and leading KOLs around the world attended the event. Dr. Bernhard Winkler, PD/Priv. Doz MD, was invited to speak at this educational event; Dr. Winkler’s presentation was well received.

Somahlution and Heartcor hosted a cocktail reception and dinner in Leipzig, Germany with key opinion leaders in attendance. Heartcor had an exhibit booth featuring DuraGraft.